company background image
IPD

ImpediMedASX:IPD Stock Report

Market Cap

AU$217.1m

7D

11.5%

1Y

79.0%

Updated

17 Oct, 2021

Data

Company Financials +
IPD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IPD Overview

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for ImpediMed
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.078
52 Week LowAU$0.18
Beta2.97
1 Month Change31.82%
3 Month Change38.10%
1 Year Change79.01%
3 Year Change-67.05%
5 Year Change-91.21%
Change since IPO-82.94%

Recent News & Updates

Aug 25
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

IPDAU Medical EquipmentAU Market
7D11.5%-0.7%0.9%
1Y79.0%-4.9%20.2%

Return vs Industry: IPD exceeded the Australian Medical Equipment industry which returned -4.9% over the past year.

Return vs Market: IPD exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is IPD's price volatile compared to industry and market?
IPD volatility
IPD Beta2.97
Industry Beta0.57
Market Beta1

Stable Share Price: IPD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IPD's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199973Rick Carreonhttps://www.impedimed.com

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics.

ImpediMed Fundamentals Summary

How do ImpediMed's earnings and revenue compare to its market cap?
IPD fundamental statistics
Market CapAU$217.08m
Earnings (TTM)-AU$20.71m
Revenue (TTM)AU$8.41m

25.8x

P/S Ratio

-10.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPD income statement (TTM)
RevenueAU$8.41m
Cost of RevenueAU$1.60m
Gross ProfitAU$6.81m
ExpensesAU$27.51m
Earnings-AU$20.71m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin80.95%
Net Profit Margin-246.24%
Debt/Equity Ratio0%

How did IPD perform over the long term?

See historical performance and comparison

Valuation

Is ImpediMed undervalued compared to its fair value and its price relative to the market?

8.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: IPD (A$0.15) is trading above our estimate of fair value (A$0.13)

Significantly Below Fair Value: IPD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IPD is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: IPD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPD is overvalued based on its PB Ratio (8.5x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

60.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: IPD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IPD's is expected to become profitable in the next 3 years.

Revenue vs Market: IPD's revenue (44.8% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: IPD's revenue (44.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPD's Return on Equity is forecast to be low in 3 years time (8.3%).


Past Performance

How has ImpediMed performed over the past 5 years?

7.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPD is currently unprofitable.

Growing Profit Margin: IPD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: IPD has a negative Return on Equity (-81.16%), as it is currently unprofitable.


Financial Health

How is ImpediMed's financial position?


Financial Position Analysis

Short Term Liabilities: IPD's short term assets (A$25.7M) exceed its short term liabilities (A$8.1M).

Long Term Liabilities: IPD's short term assets (A$25.7M) exceed its long term liabilities (A$557.0K).


Debt to Equity History and Analysis

Debt Level: IPD is debt free.

Reducing Debt: IPD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IPD has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 0.5% each year.


Dividend

What is ImpediMed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IPD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Rick Carreon

9.25yrs

Tenure

AU$2,033,059

Compensation

Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and joined as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon has e...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD1.51M) is above average for companies of similar size in the Australian market ($USD556.28K).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IPD's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: IPD's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.


Top Shareholders

Company Information

ImpediMed Limited's employee growth, exchange listings and data sources


Key Information

  • Name: ImpediMed Limited
  • Ticker: IPD
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$217.080m
  • Shares outstanding: 1.50b
  • Website: https://www.impedimed.com

Number of Employees


Location

  • ImpediMed Limited
  • 50 Parker Court
  • Unit 1
  • Pinkenba
  • Queensland
  • 4008
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.